Pharmaceutical composition for preventing phlegm from forming and stopping coughing

A technology for reducing phlegm and relieving cough and composition, which is applied in the field of medicine and can solve problems such as physical exertion and destruction of alveolar wall elastic tissue

Pending Publication Date: 2022-04-22
SHANGHAI PULMONARY HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, if the cough persists and turns from acute to chronic, it often brings great pain to the patient, such as chest tightness, itchy throat, asthma, etc., and a long-las

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing phlegm from forming and stopping coughing
  • Pharmaceutical composition for preventing phlegm from forming and stopping coughing
  • Pharmaceutical composition for preventing phlegm from forming and stopping coughing

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] The preparation of embodiment 1 glycyl prolyl serine oral solution (unit: g)

[0084] Raw materials Prescription 1 Prescription 2 Prescription 3 Glycylprolylserine 2g 4g 8g Sorbitol 30g 30g 30g Potassium sorbate 0.15g 0.15g 0.15g Citric Acid Monohydrate 0.2g 0.2g 0.2g 0.1M hydrochloric acid / sodium hydroxide Appropriate amount Appropriate amount Appropriate amount Solution pH 6.5-7.5 6.5-7.5 6.5-7.5 Purified water to a volume of 100ml 100ml 100ml

[0085] .

[0086] illustrate:

[0087] According to the low, middle and high doses administered to the mice, it is converted into the adult dose according to the body weight (the adult body weight is 60kg, the conversion coefficient is 0.11, and each time taking 5ml oral liquid, each time taking about 0.1g, 0.2g or 0.4g)

[0088] Oral liquid preparation process is as follows:

[0089] 1) Take glycylprolylserine, sorbitol, potassium sorbate, citric...

Embodiment 2

[0094] The preparation of embodiment 2 capsules

[0095] Raw materials Prescription 1 Prescription 2 Prescription 3 Glycylprolylserine 100g 200g 400g microcrystalline cellulose 42g 84g 168g Mannitol 42g 84g 168g Croscarmellose Sodium 10g 20g 40g Micropowder silica gel 4g 8g 16g Sodium stearyl fumarate 2g 4g 8g Weight of the contents of the unit dosage capsule 200mg 400mg 800mg HPMC capsule shell 1000 capsules 1000 capsules 1000 capsules Co-made 1000 capsules 1000 capsules 1000 capsules

[0096] .

[0097] According to the low, medium and high doses given to mice, it is converted into adult dose according to body weight (adult body weight is 60kg, the conversion coefficient is 0.11, take one capsule each time, and take 0.1g, 0.2g or 0.4g each time)

[0098] Preparation Process:

[0099] 1) Take the prescription amount of glycylprolylserine, microcrystalline cellulose, mannitol,...

Embodiment 3

[0106] The preparation of embodiment 3 tablet

[0107]

[0108]

[0109] According to the low, middle and high doses administered to mice, it is converted into an adult dose according to the body weight (the adult body weight is 60kg, the conversion coefficient is 0.11, and one tablet is taken each time, 0.1g, 0.2g or 0.4g each time)

[0110] Preparation Process:

[0111] 1) Take the prescription amount of glycylprolylserine, microcrystalline cellulose, mannitol, pulverize, pass through a 80-mesh sieve, and set aside;

[0112] 2) Take the prescription amount of glycylprolylserine, microcrystalline cellulose, and mannitol, mix evenly, add an appropriate amount of purified water, and make a soft material;

[0113] 3) Take the soft material obtained in step 2), prepare wet granules with a 24-mesh sieve, dry at 60°C, and granulate with a 24-mesh sieve to obtain drug-loaded granules;

[0114] 4) Take the drug-loaded granules obtained in step 3), add croscarmellose sodium, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for preventing phlegm from forming and stopping coughing. In particular to application of glycyl prolyl serine to preparation of a medicine for preventing phlegm from forming and stopping cough, a medicine composition containing glycyl prolyl serine and used for preventing phlegm from forming and stopping cough and a preparation method of the medicine composition. The phlegm reducing and cough stopping effects of glycyl prolyl serine are found for the first time, the glycyl prolyl serine is further prepared into the oral preparation, and it is proved through a mouse toxicity test, a mouse cough model, a guinea pig cough model, a mouse expectoration test model and a beagle cough phlegm test model that after the glycyl prolyl serine is prepared into the oral pharmaceutical composition, the effect of reducing phlegm and stopping cough is achieved. The obvious effects of reducing phlegm and stopping coughing are achieved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for reducing phlegm and relieving cough and a preparation method. Background technique [0002] With the acceleration of urbanization and industrial processes, the disorderly discharge of pollutants such as industrial waste gas, vehicle exhaust, and coal smoke has caused serious excess of dust, bacteria, viruses, and inhalable particulate matter in the air. Together, smog is formed. In this weather, when people travel or in daily work and life, tiny particles in the air (mainly referring to particles with a diameter less than or equal to 2.5 microns, namely PM2. When guarding against, it invades the human respiratory tract and lung lobes. [0003] After the sulfur dioxide in the "smog" component is inhaled by the human body into the respiratory tract, it is easily soluble in water, so most of it is blocked in the upper respiratory tract....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/06A61P11/10A61P11/14
CPCA61K38/06A61P11/10A61P11/14
Inventor 黄靖赖文君
Owner SHANGHAI PULMONARY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap